BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
67.78
-2.94 (-4.16%)
Feb 20, 2026, 10:23 AM EST - Market open
Revenue by Segment
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 |
|---|
Identifying and Advancing Transformative Medicines to Treat Patients | 221.90M | 9.30M | 77.65M | 69.72M | 8.25M | | | |
Identifying and Advancing Transformative Medicines to Treat Patients Growth | 2285.27% | -88.02% | 11.38% | 745.14% | -79.66% | | | |
| 221.90M | 9.30M | 77.65M | 69.72M | 8.25M | | | |
| 2285.27% | -88.02% | 11.38% | 745.14% | -79.66% | | | |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 |
|---|
| - | - | - | 69.72M | 8.25M | | | |
| - | - | - | 745.14% | -79.66% | | | |
Europe, Middle East, and Africa (EMEA) | 132.03M | - | - | - | - | | | |
| 76.56M | 1.35M | - | - | - | | | |
Asia-Pacific (APAC) Growth | 5575.31% | - | - | - | - | | | |
| - | 7.90M | 76.79M | - | - | | | |
| - | -89.72% | - | - | - | | | |
| 208.59M | 9.25M | 76.79M | 69.72M | 8.25M | | | |
| 2155.69% | -87.96% | 10.15% | 745.14% | -79.66% | | | |
Source: S&P Global Market Intelligence.